Skip to content
Screener

Xencor XNCR Financing Cash Flow

Financing Cash Flow at other companies

Amgen logo
AmgenAMGN
-$1.48B+44.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$1.22B-8.5%
Janux Therapeutics logo
Janux TherapeuticsJANX
$2.24M+135%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$6.39M
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$1.21M+104%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
-$37.56K

Other financials

Income statement

See full
Revenue$51.2M+17.5%
Operating income-$37.1M-11.7%
Net income-$21.7M+29.5%
EPS (diluted)-$0.29+29.3%

Balance sheet

See full
Cash & equivalents$44.7M+0.5%
Total debt$170.1M-20.1%
Total equity$503.2M-18.9%
Total assets$725.0M-17.6%

Cash flow

See full
Operating cash flow-$55.7M-53.0%
CapEx$538.0K+40.5%
Free cash flow-$56.2M-52.9%

Valuation

See full
Market cap$1.6B+221%
Enterprise value$1.73B+159%
P/S15.3×+11.9×

Profitability

See full
Operating margin-205.8%-2,501pp
Net margin-155.6%+78.8pp
FCF margin-198.4%-1,485pp

Returns & leverage

See full
Return on equity-29.1%+0.2pp
Debt / equity0.3×0.0×
Current ratio6.4×+1.1×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Xencor’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:02 PM EDT
Fiscal quarter
Q4 FY2028
Calendar quarter
Q4 2028
Accession
0001326732-26-000056
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Proceeds from the exercises of stock options9852,974
Proceeds from issuance of common stock under the Employee Stock Purchase Plan996662
Cash paid to acquire noncontrolling interest(1,725)
Net cash provided by financing activities1,9811,911
Net (decrease) increase in cash, cash equivalents, and restricted cash(9,508)3,466
Cash, cash equivalents, and restricted cash, beginning of period54,36241,262
Cash, cash equivalents, and restricted cash, end of period$44,854$44,728
Supplemental disclosure of cash flow information

Item 1. Financial Statements

FAQ

What is Xencor's financing cash flow?
Xencor (XNCR) reported financing cash flow of $1.03M in Q2 2026.
How has Xencor's financing cash flow changed year-over-year?
Xencor's financing cash flow increased by 55.7% year-over-year, from $662K to $1.03M.
What is the long-term trend for Xencor's financing cash flow?
Over 4 years (2021 to 2025), Xencor's financing cash flow has grown at a -33.9% compound annual growth rate (CAGR), from $43.04M to $8.23M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Xencor's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude